Unknown

Dataset Information

0

Treatment with Lanreotide Depot Following Octreotide Long-Acting Release Among Patients with Gastroenteropancreatic Neuroendocrine Tumors.


ABSTRACT: Objective: To examine patients with metastatic gastroenteropancreatic neuroendocrine tumors (GEP-NETs) who receive sequential treatment with somatostatin analogs. Materials and Methods: This retrospective chart review examined lanreotide depot/autogel tolerability and efficacy among GEP-NET patients who received lanreotide after octreotide long-acting release (LAR) at Tufts University Medical Center. Information obtained included background patient characteristics, dosing, adverse events (AEs), radiologic response, and biochemical markers. Results: Patients (n = 16; 43-81 years; mean age, 64.25 years; 11 female) with nonfunctional, low-grade GEP-NETs receiving octreotide LAR 30-60 mg were transitioned to lanreotide because of patient decision (n = 6), disease progression (n = 6), AEs (n = 2), poor tolerance (n = 1), and injection discomfort/pain (n = 1). Lanreotide doses started at 120 mg (n = 13), 90 mg (n = 1), or 60 mg (n = 2); 8 patients received concomitant therapies, mostly liver-directed (radiofrequency ablation/radioembolization). AEs associated with lanreotide experienced by ≥2 patients were fatigue, diarrhea, nausea, hypertension, pancreatic enzyme deficiency, and hyperglycemia. Radiologic treatment responses of the combination of lanreotide with other therapeutic modalities included complete response (n = 1), partial response (n = 5), and stable disease (n = 9). One patient had radiologic progression. Serum serotonin and chromogranin levels decreased, but urinary 5-hydroxyindoleacetic acid levels appeared relatively unchanged. Conclusion: Among post-octreotide GEP-NET patients, including those with disease progression or poor octreotide tolerance, lanreotide alone or with concomitant therapies was well tolerated and associated with radiologic responses.

SUBMITTER: Saif MW 

PROVIDER: S-EPMC6371583 | biostudies-literature | 2018

REPOSITORIES: biostudies-literature

altmetric image

Publications

Treatment with Lanreotide Depot Following Octreotide Long-Acting Release Among Patients with Gastroenteropancreatic Neuroendocrine Tumors.

Saif Muhammad Wasif MW   Fu Julie J   Smith Melissa H MH   Weinstein Barbara B   Relias Valerie V   Daly Kevin P KP  

Journal of pancreatic cancer 20181001 1


<b>Objective:</b> To examine patients with metastatic gastroenteropancreatic neuroendocrine tumors (GEP-NETs) who receive sequential treatment with somatostatin analogs. <b>Materials and Methods:</b> This retrospective chart review examined lanreotide depot/autogel tolerability and efficacy among GEP-NET patients who received lanreotide after octreotide long-acting release (LAR) at Tufts University Medical Center. Information obtained included background patient characteristics, dosing, adverse  ...[more]

Similar Datasets

| 2233976 | ecrin-mdr-crc
| S-EPMC9509059 | biostudies-literature
| S-EPMC10243760 | biostudies-literature
| S-EPMC6643159 | biostudies-literature
| S-EPMC9681944 | biostudies-literature
| S-EPMC5421960 | biostudies-literature
| 2235970 | ecrin-mdr-crc
| S-EPMC4609826 | biostudies-literature
| S-EPMC5611500 | biostudies-other
| S-EPMC11394651 | biostudies-literature